RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
July 22, 2020 07:00 ET
|
RedHill Biopharma Ltd.
Phase 2/3 study process initiated in Brazil and Mexico The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia Enrollment planned...
RedHill Biopharma получила одобрение для проведения фазы 2/3 COVID-19 исследования в России
July 22, 2020 02:47 ET
|
RedHill Biopharma Ltd.
Заявка на клинические испытания одобренна в России для фазы 2/3 исследования с опаганибом у пациентов с тяжелой формой COVID-19 после недавнего одобрения в Великобритании и аналогичной заявки в...
RedHill Biopharma Seeks SEC Review of Suspicious Trading Activity
July 21, 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., July 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced today it is...
RedHill Biopharma获准在俄罗斯进行2/3阶段新冠肺炎药物研究
July 20, 2020 05:11 ET
|
RedHill Biopharma Ltd.
继近期在英国获得批准和在意大利提交类似申请后，opaganib用于重症新冠肺炎患者的2/3期研究临床试验申请在俄罗斯获得批准 —— 此项2/3阶段研究力争在多达40个临床地点招募270名受试者；招募活动计划在本月晚些时候启动，并计划在2020年第4季度提交紧急使用授权申请 —— 同时，美国使用opaganib治疗重症新冠肺炎患者的2a期研究正在快速推进，目前已招募到25%以上的患者 ——...
RedHill Biopharma 獲准在俄羅斯進行第 2/3 期 COVID-19 研究
July 20, 2020 05:11 ET
|
RedHill Biopharma Ltd.
當英國最近批准並在意大利提交類似申請後，俄羅斯批准將 opaganib 用於嚴重 COVID-19 患者以進行第 2/3 期研究的臨床試驗申請 -- 第 2/3 研究旨在從多達 40 個臨床中心納入 270 名受試者；計劃納入工作將在本月稍後啟動，並計劃於 2020 年第四季提交緊急使用授權申請 -- 同時，美國第 2a 期將 opaganib 用於嚴重 COVID-19...
RedHill Biopharma erhält Genehmigung für Phase-II/III-COVID-19-Studie in Russland
July 20, 2020 05:11 ET
|
RedHill Biopharma Ltd.
Antrag für klinische Phase-II/III-Studie zur Behandlung schwer erkrankter COVID-19-Patienten mit Opaganib in Russland nach kürzlich in Großbritannien erteilter Genehmigung ebenfalls genehmigt;...
RedHill Biopharma reçoit l'approbation pour une étude de phase 2/3 sur un traitement contre la COVID-19 en Russie
July 20, 2020 05:11 ET
|
RedHill Biopharma Ltd.
Une demande d'essai clinique a été approuvée en Russie pour l'étude de phase 2/3 sur l'opaganib chez les patients atteints d'une forme grave de la COVID- 19 suite à une récente approbation au...
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
July 16, 2020 08:00 ET
|
RedHill Biopharma Ltd.
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy--The Phase 2/3 study...
RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum
July 01, 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., July 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma erhält Genehmigung für Phase-II/III-Studie zur Behandlung von COVID-19-Patienten mit Opaganib in Großbritannien
July 01, 2020 01:00 ET
|
RedHill Biopharma Ltd.
In die multizentrische, randomisierte, doppelblinde und placebokontrollierte Parallelarmstudie der Phasen II/III zu Opaganib sollen 270 schwer erkrankte COVID-19-Patienten an bis zu 40 Prüfzentren in...